10:54 AM EDT, 09/04/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday the US Food and Drug Administration has accepted the resubmission of its New Drug Application for AXS-07 to potentially treat migraine.

The FDA has classified it as a Class 2 resubmission, with a Prescription Drug User Fee Act target action date of Jan. 31, 2025, the company said.

The company's shares were up about 2% in recent trading.

Price: 91.42, Change: +1.77, Percent Change: +1.97